# US 2024/0189425 A1 · Chimeric antigen receptor with modified hinge and transmembrane domain and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189425 A1
- Document ID: US20240189425A1
- Status: Published application
- Kind: A1
- Application number: 18/583,721
- Filed: 2024-02-21
- Published: 2024-06-13
- Earliest claimed: 2022-06-24
- Assignees: Orgenesis Inc.
- Applicants: Orgenesis Inc.
- Inventors: BUO CHEN; Xiangqun LI
- Web page: https://patentgrep.com/patent/US20240189425A1

## CPC

- A61K 40/4211: {CD19 or B4}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a chimeric antigen receptor (CAR) molecule comprising a modified hinge and transmembrane domain (HTM-1), wherein the modified hinge and transmembrane domain comprises the amino acid sequence of SEQ ID NO:2. Cells expressing CAR with the modified HTM-1 domain disclosed herein are expected to have enhanced anti-tumor activities with reduced release of pro-inflammatory cytokines.

## Claims

### Claim 1

An isolated chimeric antigen receptor (CAR) molecule comprising an antigen binding domain, a hinge and transmembrane domain, a costimulatory domain, and an intracellular signaling domain, wherein the hinge and transmembrane domain comprises the amino acid sequence of SEQ ID NO:2.

### Claim 2 (depends on 1)

The isolated CAR of claim 1, wherein the hinge and transmembrane domain is encoded by a nucleotide sequence comprising the sequence of SEQ ID NO:1.

### Claim 3 (depends on 1)

The isolated CAR of claim 1, wherein the antigen binding domain is a single chain antibody or single chain antibody fragment.

### Claim 4 (depends on 1)

The isolated CAR of claim 1, wherein the antigen binding domain binds to a target antigen selected from the group consisting of CD19, CD20, CD22, CD33, CD123, BCMA, CLL1, CD7, CS1, CEA, AFP, PSMA, GPC3, GD2, EGFRVIII, NKG2D, Mesothelin, Claudin 18.2, ROR3, and Muc1.

### Claim 5 (depends on 1)

The isolated CAR of claim 1, wherein the antigen binding domain comprises a scFv that binds to CD19, said scFv comprises the amino acid sequences of SEQ ID NOs:4 and 6.

### Claim 6 (depends on 1)

The isolated CAR of claim 1, wherein the costimulatory domain comprises a functional signaling domain of a protein selected from the group consisting of OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4-1BB (CD137).

### Claim 7 (depends on 1)

The isolated CAR of claim 1, wherein the intracellular signaling domain comprises an intracellular signaling domain of CD3 zeta, or FcR gamma, or a functional fragment thereof.

### Claim 8 (depends on 1)

A nucleic acid construct comprising one or more nucleic acid sequences, said nucleic acid sequences encode the isolated CAR of claim 1, or fragments thereof.

### Claim 9 (depends on 8)

An expression vector comprising the nucleic acid construct of claim 8.

### Claim 10 (depends on 9)

A cell comprising the expression vector of claim 9.

### Claim 11 (depends on 10)

The cell of claim 10, wherein the cell is an immune cell.

### Claim 12 (depends on 11)

The cell of claim 11, wherein the immune cell is a T cell.

### Claim 13 (depends on 10)

A composition comprising the cell of claim 10 and a pharmaceutically acceptable carrier.
